ABSTRACT
Bioresorbable vascular scaffolds (BVSs) have several advantages over current metallic drug-eluting stents (DESs). The large studies with specific end points and long-term follow-up may be necessary to confirm that these new devices may obtain better outcome after percutaneous treatment of coronary artery disease (CAD) patients. Non-invasive coronary imaging with coronary computed tomography angiography (CCTA) will play a major research and clinical role in the follow-up of patients treated with BVSs. Rapid progress of multi-slice computed tomography (MSCT) technology has permitted more accurate coronary images with improved spatial and temporal resolution and has resulted in the recognition of CCTA as a dependable noninvasive diagnostic modality for the evaluation of computer aided design (CAD). The interesting information provided by CCTA assessment are the follow-up findings after BVSs treatment of complex coronary disease such as bifurcation lesions, chronic total occlusions (CTO), and long or diffuse lesions.
